Some of the world's largest technology companies are making substantial moves into the life sciences space through acquisitions, platform launches, partnerships and board appointments that are signaling the deepening convergence between artificial intelligence and biology. In our view, relative to any other domain, AI could have the most profound impact on biology, medicine and healthcare.
Biology involves enormous complexity. The human body includes about 35 trillion cells, each with a genome of about 3.2 billion base pairs. Researchers estimate the space of potential drug-like molecules at more than 1060, a scale well beyond the ability of human-driven experimental methods to explore systematically. And these examples barely scratch the surface of biological complexity.
Meanwhile, advances in multiomics sequencing are generating biological data at a scale that exceeds the unaided capacity of human beings to interpret effectively. The combination of vast bi
